UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 7, 2006

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-31812**	**58-2301143**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

111 Barclay Boulevard **Lincolnshire, Illinois**	**60069**
(Address of principal executive offices)	(Zip Code)

(847) 478-0500
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Representatives of BioSante Pharmaceuticals, Inc. ("BioSante") intend to make presentations at investor conferences and in other forums using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. BioSante is furnishing the text of these slides pursuant to the Securities and Exchange Commission's Regulation FD. This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. BioSante expects to use these slides, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the remainder of 2006.

By filing this Current Report on Form 8-K and furnishing this information, BioSante makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the slides is summary information that is intended to be considered in the context of BioSante's Securities and Exchange Commission ("SEC") filings and other public announcements that BioSante may make, by press release or otherwise, from time to time. BioSante undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

When included in this Current Report on Form 8-K, the words "expects," "intends," "anticipates," "believes," "estimates," and analogous expressions are intended to identify forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited, to, in no particular order: the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. More detailed information on these and additional factors which could affect BioSante's operating and financial results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K. BioSante urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, BioSante undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits*.

Exhibit No.	**Description**
99.1	BioSante Pharmaceuticals, Inc. Investor Presentation (furnished herewith)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSANTE PHARMACEUTICALS, INC.

By: /s/ Stephen M. Simes
Stephen M. Simes
President and Chief Executive Officer

Dated: November 7, 2006

BIOSANTE PHARMACEUTICALS, INC.
CURRENT REPORT ON FORM 8-K

EXHIBIT INDEX

Exhibit No.	Description	Method of Filing
99.1	BioSante Pharmaceuticals, Inc. Investor Presentation	Furnished herewith


BioSante
Pharmaceuticals


To the extent any statements made in this presentation deal with information that is not historical, these are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of BioSante's control and are subject to various risk factors that could cause BioSante's results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the inherent risk of competition in the marketplace, clinical outcomes in drug development programs, regulatory risks related to proprietary rights and market acceptance. cause such material differences are identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent Forms 10-K and 10Q, which discussion also is incorporated herein by reference. Bio-E-Gel nor LibiGel will be approved by the FDA, that LibiGel clinical development will not be successful or will be discontinued, that safety and efficacy protocols will not be finalized and Phase III will not be started in a timely manner or at all the first product in its category to be approved by the FDA. forward-looking statements speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
BioSante
Pharmaceuticals

Mission

Increase stockholder value by developing and commercializing BioSante's near and long-term product pipeline

- Ø hormone therapy products,
- Ø nanotechnology
  - ü vaccines, and
  - ü protein delivery

Investment Highlights

- **Hormone therapy (HT) gel portfolio**
  - **Bio-E-Gel® for reduction of hot flashes**
  - **LibiGel® for female sexual dysfunction**
  - **Bio-E+P-Gel™ for reduction of hot flashes**
  - **Bio-T-Gel™ for male hypogonadism**
- **Calcium phosphate nanotechnology (CAP)**
  - **Vaccines**
    - **Bio-defense vaccines, e.g., anthrax**
    - **Adjuvanted avian flu vaccine**
  - **Drug delivery for proteins and peptides (non-injected)**
- **Management's proven ability to increase stockholder value**

BioSante Pharmaceuticals

HT Product Portfolio

BioSante Pharmaceuticals

Bio-E-Gel® (estradiol gel)

Indication: **Once daily transdermal gel for treatment of menopausal women**

Symptoms: **Hot flashes, vaginal atrophy, decreased libido and osteoporosis**

Market Size: **Data from IMS Health [U.S. only 2005)]:**

- **Estrogentherapy(ET)market: $1.3 billion**
- **Transdermal segment: about $250 million**
  - **Estimated to reach $400million in 2008**

Status: **NDA submitted Q1 2006**

- **Significant reduction in frequency and severity of hot flashes**
- **Three effective doses shown**
- **Lowest effective dose identified**
- **50% lower E than currently on market**
- **Launch in 2007**

BioSante Pharmaceuticals

Mean Change From Baseline in Daily Moderate-to-Severe Hot Flash Rate by Bio-E-Gel® Dosage



* Statistically significant from placebo p<0.0001 through Week 12 (p=.0002 for Low Dose at Weeks 5 and 6).
Baseline moderate-to-severe hot flash rates ranged from 12.9 – 13.5 across treatment groups.

BioSante Pharmaceuticals

Mean Change From Baseline in Severity of Hot Flashes by Bio-E-Gel® Dosage



Severity scale: 1=mild, 2=moderate, 3=severe.
Baseline hot flash rates Severity ranged from 2.3 – 2.4 across treatment groups.
* Statistically significant from placebo p<0.0001, p<0.001 or p<0.01 through Week 12.

BioSante Pharmaceuticals

Bio-E-Gel® Marketing Strategy

- **Expect launch in 2007**
  - **small surface area (upper arm)**
  - **fast drying (one to two minutes)**
  - **no residue or evidence of use**

- **Target audience: the 14,000 high volume prescribing Ob/Gyns in the U.S. who prescribe about 70% of the $1.3 billion market for estrogen therapy**

- **Can be launched with approximately 50 sales representatives**

- **Seeking sales/marketing partner to launch Bio-E-Gel®**

BioSante Pharmaceuticals

LibiGel® (testosterone gel for women)

Indication: **Female sexual dysfunction (FSD)**

Symptoms: **Lack of sexual desire, arousal or pleasure**

Market Size: **- 43% of women experience FSD**

- Lack of sexual desire is largest segment

- P&G's Intrinsa "patch"

- **approved in Europe; planning launch**
- **reportedly on hold in U.S.**
- **P & G "considering options" in U.S**

- Estimate U.S. market above $2 billion

Status: **Phase II clinical trial completed - statistical increase in satisfying sexual events**
Phase III safety and efficacy protocols to be finalized with FDA

Objective: **Phase III to start in late 2006/early 2007 LibiGel potentially could be the first FSD Rx product to market in U.S.**

BioSante Pharmaceuticals

Comparative Results

	BioSante/ LibiGel®	P&G/ Intrinsa	P&G/ Intrinsa
Study Design	3 month Phase II 150 mcg/day N=46 SM	6 month Phase III 300 mcg/day N=562 SM	6 month Phase III 300 mcg/day N=533 SM
% increase in sexual events from baseline	238%*	74%*	51%*
# increase active v. pbo	5.0 v. 1.6*	2.13 v. 0.98*	1.56 v. 0.73*
Application site reactions	rare	~ 30%	~ 30%

*Statistically significant versus baseline and placebo, respectively
SM = surgically menopausal

BioSante Pharmaceuticals

Pipeline Potential

The $2.5 billion U.S. hormone therapy market is poised for growth based on demographics of aging (e.g., menopause)

Female sexual dysfunction could add $2.0 to $4.0 billion



BioSante Pharmaceuticals

BioSante's Product Pipeline



BioSante Pharmaceuticals

BioSante Pharmaceuticals, Inc.

Corporate Summary

Trading Data

Ø **American Stock Exchange (Amex)**	**BPA**
Ø **Common stock outstanding**	**23.0 million**
Ø **Warrants** ($2.15, $2.75 and $7.00)	**3.0 million**
Ø **Employee options** (average exercise price of $3.61)	**1.0 million**
Ø **Fully diluted shares**	**27.0 million**

BioSante Pharmaceuticals

Financial Highlights

- **Cash at September 30, 2006**

  Approximately $10.3 million

- **Burn rate for third quarter 2006**

  Approximately $600,000-$650,000/month

- **No long-term debt**

Key Product Development Milestones

- **Bio-E-Gel®**
  - ü **NDA submitted in Q1-2006**
  - ü **three effective doses shown**
  - ü **lowest effective dose identified**
  - ü **launch estimated in 2007**
- **LibiGel®**
  - ü **initiate Phase III clinical studies in female sexual dysfunction in 2006/early 2007**
- **CaP Bio-Vant™ vaccine adjuvant**
  - ü **pursue continued development of biodefense and avian flu vaccines**

BioSante Pharmaceuticals


BioSante
Pharmaceuticals